Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF - Get Free Report)'s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $11.83 and traded as low as $11.20. Ono Pharmaceutical shares last traded at $11.20, with a volume of 7,370 shares traded.
Ono Pharmaceutical Price Performance
The stock has a market cap of $5.17 billion, a PE ratio of 10.58 and a beta of 0.74. The company has a quick ratio of 2.80, a current ratio of 3.55 and a debt-to-equity ratio of 0.14. The company's fifty day moving average is $10.08 and its 200 day moving average is $11.76.
Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported $0.21 EPS for the quarter. Ono Pharmaceutical had a net margin of 15.15% and a return on equity of 9.10%.
About Ono Pharmaceutical
(
Get Free Report)
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
Featured Stories
Before you consider Ono Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.
While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
